Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Verkazia | cyclosporine | Severe vernal keratoconjunctivitis, pediatric (≥4 years) | Reimburse with clinical criteria and/or conditions | Complete | ||
Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
Cubicin | Daptomycin | Skin and skin structure infections & bacteremia | Do not list | Complete | ||
Tecentriq | atezolizumab | Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecentriq | Atezolizumab | Small Cell Lung Cancer (SCLC) | Do not reimburse | Complete | ||
Champix | Varenicline tartrate | Smoking-cessation | List with clinical criteria and/or conditions | Complete | ||
Votrient | Pazopanib Hydrochloride | Soft Tissue Sarcoma | Do not reimburse | Complete | ||
N/A | Nab-paclitaxel | Solid tumours | Active |